Acceptance and management of disease in Rheumatoid Arthritis and Ankylosing Spondylitis

Children do not directly inherit Ankylosing Spondylitis (AS), but they may inherit a higher genetic risk of developing it. The condition is strongly associated with the HLA-B27 gene, which can be passed from parents to children. However, most children who inherit HLA-B27 never develop AS. Environmental factors, immune responses, and other genes also play a role. Having a parent with AS increases a child’s risk compared to the general population, but it does not mean the child will definitely develop the disease.

MRI plays a key role in the early diagnosis of Ankylosing Spondylitis (AS) because it can detect active inflammation in the sacroiliac joints and spine before permanent damage appears on X-rays. Unlike X-rays, which show changes only in later stages, MRI can identify bone marrow edema and early inflammatory changes, allowing doctors to diagnose AS sooner. Early MRI diagnosis helps start treatment earlier, which can reduce pain, control inflammation, and slow disease progression.

Rheumatoid Arthritis (RA) and osteoarthritis (OA) are different types of joint diseases with distinct causes and characteristics. RA is an autoimmune condition, where the immune system attacks the joint lining, leading to inflammation, pain, swelling, and potential joint deformity. It often affects smaller joints like the hands and wrists symmetrically and can involve other organs.

Osteoarthritis, on the other hand, is a degenerative joint disease caused by wear and tear of cartilage over time. It usually affects weight-bearing joints such as the knees, hips, or spine, and is more common with aging. OA causes pain, stiffness, and reduced mobility but typically does not involve systemic inflammation or other organs. In short, RA is inflammatory and autoimmune, while OA is mechanical and degenerative.

DMARDs (Disease-Modifying Anti-Rheumatic Drugs) are a class of medications used to slow the progression of Rheumatoid Arthritis (RA) rather than just relieve symptoms. Unlike painkillers or anti-inflammatory drugs, DMARDs target the underlying immune system dysfunction that causes joint inflammation and damage.

Common DMARDs include methotrexate, sulfasalazine, and hydroxychloroquine, and they are often considered the first-line treatment for RA. By reducing inflammation and preventing joint erosion and deformity, DMARDs help patients maintain mobility, function, and long-term quality of life. These medications are often combined with lifestyle measures and other therapies for optimal disease control.

Biologic drugs are recommended for Rheumatoid Arthritis (RA) when conventional treatments, such as traditional DMARDs, are not sufficient to control disease activity. Biologics are targeted therapies that block specific molecules or immune pathways responsible for inflammation, such as TNF-alpha, IL-6, or B-cell activity.

They are typically prescribed for patients with moderate to severe RA, especially those who continue to experience joint pain, swelling, or progressive damage despite standard DMARD therapy. Biologics can help reduce inflammation, prevent joint destruction, improve physical function, and enhance quality of life. Because these medications can affect the immune system, they require close monitoring for infections and other potential side effects.

Yes, Rheumatoid Arthritis can affect organs beyond the joints. Ongoing inflammation may involve the lungs, heart, and eyes, leading to issues such as breathing difficulties, increased cardiovascular risk, and eye dryness or inflammation. With early diagnosis, regular monitoring, and proper treatment, these complications can often be prevented or well managed.